Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.